Download presentation
Presentation is loading. Please wait.
PublishHayden Torres Modified over 10 years ago
1
Please Be Sure That You Have Your Audience Response Keypad With You. You Will Need It During This Session.
2
Using your Audience Response Keypad Questions will be displayed along with the available answers Questions will be displayed along with the available answers When the countdown clock appears, press and release the button that best represents your answer When the countdown clock appears, press and release the button that best represents your answer Your last answer will be recorded Your last answer will be recorded The quicker you respond correctly, the more points you will be awarded The quicker you respond correctly, the more points you will be awarded There is no need to press GO or ? There is no need to press GO or ?
3
In S. America, the percent of sites enrolling > 0.5pts/mo is: A. A.25% B. B.55% C. C.75% D. D.>90%
4
The target percentage for sites enrolling > 0.5 pts/mo is: A. A. 50% B. B. 75% C. C. >80% D. D. 100%
5
Data Submission/entry should take place: A. A. <2 days after visit B. B. <10 days after visit C. C. Within 1 month after visit
6
What is the primary reason that rapid data submission is so important? A. A. Accurate up to date information can be provided to the Data Safety Monitoring Board B. B. Payment to site can be made faster C. C. Protocol adherence can be assessed D. D. Allows the sponsor to review unblinded data
7
Why is the rate of permanent discontinuation of study drug of 21% worthy of discussion? A. A.The rate diminishes our ability to demonstrate superiority B. B.The rate improves our ability to demonstrate superiority C. C.The Regulatory Authorities may decide that the rate is too high and will not review the trial results
8
The achieved LDL levels observed thus far in IMPROVE- IT range from: A. A.~100-125mg/dL (2.5-3.0 mMol/L) B. B.~53-62 mg/dL (1.4-1.6 mMol/L) C. C.~25-50 mg/dL (0.6-1.3 mMol/L) D. D.None of the above
9
The Key Factor associates with enrollment success is: A. A.RC level of involvement = 25% B. B.Screening 1x/day C. C.Checking with CCU and Cath Lab schedules D. D.Involvement of PI
10
Informed Consent should be undertaken by: A. A.Research Coordinator B. B.Local MD/GP C. C.Principal Investigator D. D.RC and PI with local MD support
11
Which of the following best describes the importance of trial commitment by the Research Team? A. A.The level of commitment determines the overall success of trial completion B. B.Commitment by the PI generates interest locally at the site C. C.Protects the patients enrolled in the trial from unnecessary exposure to study drug
12
Elevations in HDL-C are associated with low levels of LDL A. A.True B. B.False
13
Lower levels of HDL-C are found in patients: A. A.Who exercise B. B.Who consume a low saturated fat diet C. C.Who are obese and sedentary D. D.Consume 2-3 alcoholic drinks/day
14
HDL action that may be anti- atherogenic include: A. A.Reverse cholesterol transport B. B.Lower the inflammatory activity C. C.Lower the formation of bile D. D.Lower the excretion of cholesterol by- products
15
Niacin increases the HDL-C levels by up to 35% A. A.True B. B.False
16
Torcetrapid works through inhibition of: A. A.Renin angiotension system B. B.Preventing thrombin formation C. C.Cholesteryl Ester Transfer Protein D. D.LDL Formation
17
What should the IMPROVE-IT enrollment window be? A. < 10 days (no change) B. < 14 days C. < 20 days D. 30 days
18
If the window was increased to greater than 10 days, what percentage (%) of enrollment increase would you expect at your site? A. No change in enrollment B. Up to 10% increase in enrollment C. 11-20% increase in enrollment D. >20 % increase in enrollment E. Dont Know
19
Lets Check the Standings
20
Please Be Sure That You Bring Your Audience Response Keypad With You Tomorrow Morning. You Will Need It During The First Session. Reminder:
21
Participant Scores 1150.64 Alfredo Lozada 1083.64 Sandra Ruiz 1048.91 Luis Cartasegna 1048.2 Maria Plastino 1033 Martín Najenson
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.